

1 **Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER**
2 **EHR Cohort**

3
4 Hanieh Razzaghi, PhD, MPH¹, Christopher B. Forrest, MD, PhD^{1,2}, Kathryn Hirabayashi, MPH¹,
5 Qiong Wu, PhD², Andrea Allen, MS¹, Suchitra Rao, MBBS, MSCS³, Yong Chen, PhD², H.
6 Timothy Bunnell, PhD¹⁸, Elizabeth A. Chrischilles, PhD⁴, Lindsay G. Cowell, PhD, MS⁵, Mollie
7 R. Cummins, PhD, RN⁶, David A Hanauer, MD, MS⁷, Miranda Higginbotham, MSHA¹,
8 Benjamin D. Horne, PhD, MStat, MPH⁸, Carol R. Horowitz, MD, MPH¹⁶, Ravi Jhaveri, MD¹²,
9 Susan Kim, MD, MMSc¹³, Aaron Mishkin, MD¹⁴, Jennifer A Muszynski, MD, MPH⁹, Susanna
10 Naggie, MD¹⁰, Nathan M. Pajor MD, MS²⁰, Anuradha Paranjape, MD, MPH¹⁴, Hayden T
11 Schwenk, MD, MPH¹⁵, Marion R. Sills, MD, MPH^{3,19}, Yacob G. Tedla, PhD¹⁷, David A.
12 Williams, PhD¹¹, Charles Bailey MD, PhD^{1,2} *on behalf of the RECOVER Consortium* A*
13 *complete list of group members appears in the supplementary materials*
14

15 Affiliations:

16 ¹ Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA

17 ² Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania,
18 Philadelphia, PA

19 ³ Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital
20 Colorado, Aurora, CO

21 ⁴ Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA

22 ⁵ Peter O'Donnell Jr. School of Public Health; Department of Immunology, School of
23 Biomedical Sciences; UT Southwestern Medical Center; Dallas, TX

24 ⁶ College of Nursing, University of Utah, Salt Lake City, UT

25 ⁷ Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI

26 ⁸ Intermountain Heart Institute, Intermountain Health, Salt Lake City, UT

27 ⁹ Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital,
28 Columbus, OH

29 ¹⁰ Division of Infectious Diseases, Duke University School of Medicine; Duke Clinical Research
30 Institute, Durham, NC

31 ¹¹ Department of Anesthesiology, University of Michigan, Ann Arbor, MI

32 ¹² Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago,
33 Chicago, IL

34 ¹³ University of California, San Francisco, Division of Rheumatology, Benioff Children's
35 Hospital, San Francisco CA

36 ¹⁴ Temple University Lewis Katz School of Medicine, Section of Infectious Diseases,
37 Philadelphia, PA

38 ¹⁵ Stanford School of Medicine, Division of Pediatric Infectious Diseases, Stanford, CA

39 ¹⁶ Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, NYC, NY

40 ¹⁷ Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center,
41 Nashville, TN

42 ¹⁸ Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, DE

43 ¹⁹ OCHIN, Inc., Portland, OR

44 ²⁰ Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and
45 University of Cincinnati College of Medicine, Cincinnati, OH

46 **Address Correspondence to:** Hanieh Razzaghi, Roberts Center for Pediatric Research, Room
47 11361, 2716 South Street, Philadelphia, PA 19146, [razzaghih@chop.edu], (267) 425-9684

48 **Short Title:** Vaccine Effectiveness Against Pediatric Long COVID

49 **Disclosures:** Dr. Mollie Cummins is employed by Doxy.me Inc., a commercial telemedicine
50 platform provider. Dr. Benjamin Horne is a member of the advisory boards of OpSis Health and
51 Lab Me Analytics, and a consultant to Pfizer (regarding clinical risk scores; funds paid to
52 Intermountain). Dr. Susanna Naggie reports research grants from Gilead Sciences and AbbVie,
53 scientific advisor/stock options from Vir Biotechnologies, consulting with no financial payment
54 from Pardes Biosciences and Silverback Therapeutics, DSMB fees from Personal Health
55 Insights, Inc, event adjudication committee fees from BMS/PRA outside the submitted work. Dr.
56 Mishkin receives Grant support from Pfizer paid directly to Institution Advisory Board for
57 Takeda. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial
58 stipend from Elsevier and Pediatric Infectious Diseases Society. Dr. Rao reports prior grant
59 support from GSK and Biofire and is a consultant for Sequiris. The remaining authors have no
60 disclosures.

61 **Funding/Support:** This research was funded by the National Institutes of Health (NIH)
62 Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery
63 (RECOVER) program of research.

64 **Disclaimer:** The views and conclusions contained in this document are those of the authors and
65 should not be interpreted as representing the official policies, either expressed or implied, of the
66 NIH.

67 **Abbreviations:** PCR – polymerase chain reaction; EHR – electronic health record; CI – 95%
68 confidence intervals; ICD-10-CM – International Classification of Diseases, version 10, clinical
69 modification; PMCA – Pediatric Medical Complexity Algorithm; US – United States of
70 America; VE – vaccine effectiveness; VIS – vaccine information system.

71 **Article Summary:** Vaccination against COVID-19 has a protective effect against long COVID
72 in children and adolescents. The effect wanes over time but remains significant at 12 months.

73 **What's Known on This Subject**

74 Vaccines reduce the risk and severity of COVID-19 in children. There is evidence for reduced
75 long COVID risk in adults who are vaccinated, but little information about similar effects for
76 children and adolescents, who have distinct forms of long COVID.

77 **What This Study Adds**

78 Using electronic health records from US health systems, we examined large cohorts of
79 vaccinated and unvaccinated patients <18 years old and show that vaccination against COVID-
80 19 is associated with reduced risk of long COVID for at least 12 months.

81

82 **Contributors' Statement**

83 Drs. Hanieh Razzaghi and Charles Bailey conceptualized and designed the study, supervised
84 analyses, drafted the initial manuscript, and critically reviewed and revised the manuscript.

85 Drs. Christopher Forrest and Yong Chen designed the study and critically reviewed and revised
86 the manuscript.

87 Ms. Kathryn Hirabayashi, Ms. Andrea Allen, and Dr. Qiong Wu conducted analyses, and
88 critically reviewed and revised the manuscript.

89 Drs. Suchitra Rao, H Timothy Bunnell, Elizabeth A. Chrischilles, Lindsay G. Cowell, Mollie R.
90 Cummins, David A. Hanauer, Benjamin D. Horne, Carol R. Horowitz, Ravi Jhaveri, Susan Kim,
91 Aaron Mishkin, Jennifer A. Muszynski, Susanna Nagie, Nathan M. Pajor, Anuradha Paranjape,
92 Hayden T. Schwenk, , Marion R. Sills, Yacob G. Tedla , David A. Williams, and Ms. Miranda
93 Higginbotham critically reviewed and revised the manuscript.

94 All authors approved the final manuscript as submitted and agree to be accountable for all
95 aspects of the work.

96 **Authorship statement:** Authorship has been determined according to ICMJE recommendations.

97

98

99 **Abstract**

100 **Objective**

101 Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it
102 protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in
103 children aged 5-17 years.

104 **Methods**

105 This retrospective cohort study used data from 17 health systems in the RECOVER PCORnet
106 electronic health record (EHR) Program for visits between vaccine availability, and October 29,
107 2022. Conditional logistic regression was used to estimate VE against long COVID with
108 matching on age group (5-11, 12-17) and time period and adjustment for sex, ethnicity, health
109 system, comorbidity burden, and pre-exposure health care utilization. We examined both
110 probable (symptom-based) and diagnosed long COVID in the year following vaccination.

111 **Results**

112 The vaccination rate was 56% in the cohort of 1,037,936 children. The incidence of probable
113 long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was
114 0.7%. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5 – 44.5) against
115 probable long COVID and 41.7% (15.0 – 60.0) against diagnosed long COVID. VE was higher
116 for adolescents 50.3% [36.3 – 61.0] than children aged 5-11 (23.8% [4.9 – 39.0]). VE was
117 higher at 6 months (61.4% [51.0 – 69.6]) but decreased to 10.6% (-26.8 – 37.0%) at 18-months.

118 **Discussion**

119 This large retrospective study shows a moderate protective effect of SARS-CoV-2 vaccination
120 against long COVID. The effect is stronger in adolescents, who have higher risk of long
121 COVID, and wanes over time. Understanding VE mechanism against long COVID requires more
122 study, including EHR sources and prospective data.

123

124

125 **Introduction**

126 SARS-CoV-2 has infected over 676 million people, and has been associated with 6.9 million
127 deaths¹. While severity has been lower in children than adults, statistics for the United States
128 (US) indicate >2100 deaths in children aged <21 years with COVID-19² and up to 2.1% of cases
129 classified as severe disease³. Further, children may experience long-term health burdens after
130 infection, collectively referred to as post-acute sequelae of SARS-CoV-2 (PASC) or “long
131 COVID”^{4,5,6}. These may represent effects of host response to the original infection in addition
132 to or instead of direct pathogen effects⁷⁻⁹. Long COVID is heterogeneous and likely
133 underdiagnosed, but symptoms such as brain fog, dyspnea, gastrointestinal dysfunction,
134 generalized pain, and fatigue can cause significant burden for children, even after mild COVID-
135 19^{4,5,10,11}. Recent research has identified specific post-acute symptoms consistent with long
136 COVID¹². Prevalence estimates vary widely^{10,12-14}. Symptoms of long COVID have been
137 reported less often and for shorter duration in children compared to adults¹¹, and higher rates
138 have been reported for adolescents than younger children¹³. It is difficult to establish how much
139 this results from differential reporting of symptoms at different ages, greater difficulty
140 distinguishing long COVID from other childhood illnesses or effects of the pandemic (*e.g.*
141 disruption of seasonal viral patterns, or of school progress)¹³. Despite the paucity of data about
142 long COVID in children, developing mitigation strategies is an important concern not only for
143 affected children but in societal discussions¹⁵ and for shaping public health policy¹⁶⁻¹⁸.

144 Vaccines provide the best opportunity for both reducing the risk of severe disease¹⁹⁻²⁴ as well as
145 short-term complications of acute infection. In adults, some reports²⁵⁻²⁹ identified a modest
146 benefit associated with vaccination in preventing long COVID in adults, while others did not^{30,31}.

147 Little data are available on the effect of vaccination on long COVID in children; in one UK study

148 including 6500 children with COVID-19, no association was seen⁴. However, to our knowledge,
149 there are no studies assessing clinical data to address this question. Efforts to learn from clinical
150 care at a large enough scale to identify underrepresented patterns provides an important
151 complement to multicenter prospective cohorts. The NIH Researching COVID to Enhance
152 Recovery (RECOVER) Initiative, which seeks to understand, treat, and prevent the post-acute
153 sequelae of SARS-CoV-2 infection (PASC, or long COVID), is employing both strategies to
154 better elucidate the condition, identify effective ways to treat patients, and support families
155 impacted by long COVID. We report results from a large-scale, national collaboration of health
156 systems from the PCORnet[®] network contributing electronic health record (EHR) data as part of
157 RECOVER's real-world program⁴⁶.

158 **Methods**

159 *Data sources:* We conducted a retrospective cohort study based on EHR data from 41 health
160 systems for children with COVID-19, a diagnosis of acute respiratory illness, fever, dyspnea, or
161 cough, or a SARS-CoV-2 vaccine. Data, extracted quarterly, were transformed to either the
162 PCORnet (v6.0) or Observational Medical Outcomes Partnership (OMOP) (v5.3) data models,
163 and forwarded to the RECOVER-PCORnet Coordinating Center. For this study, we used the s8
164 version of the data, collected in April 2023, which comprises 25,389,893 patients.

165 Institutional Review Board oversight was provided by the Biomedical Research Alliance of
166 New York, protocol # 21-08-508-380.

167 *Study Sample:* Patients were eligible if they had an in-person visit between vaccine eligibility and
168 October 29, 2022, and were between 5 and <18 years at the date of vaccine eligibility. The date
169 of SARS-CoV-2 vaccine eligibility was defined as January 01, 2021, for patients aged 12 – <18
170 years, and October 29, 2021, for patients aged 5 – <12 years, corresponding to availability of

171 vaccines. A small number of patients were excluded for documented COVID-19 before 28 days
172 after their first vaccine dose.

173 For vaccinated patients, cohort entry was the date of their first vaccine dose, while for
174 unvaccinated patients, the date of an in-person visit after vaccine eligibility was selected
175 randomly, resulting in matched distribution of entry dates between cohorts. In addition, we
176 required 1 contact between 8 days and 2 years prior to cohort entry to assess baseline health
177 characteristics. To determine long COVID outcomes, we also required at least 1 in-person visit
178 between 28 and 179 days after cohort entry.

179 *Outcomes:* The main outcomes were *diagnosed* or *probable* long COVID. A patient had
180 *diagnosed* long COVID if they had two or more visits with diagnosis codes specific for long
181 COVID; a single diagnosis code classified children as having *probable* long COVID. In
182 addition, to account for incomplete availability or use of long-COVID-specific diagnosis codes,
183 especially for patients with early signs of long COVID, , we also classified a patient as having
184 *probable* long COVID if they had COVID-19 (SARS-CoV-2 PCR or antigen positive or
185 COVID-19-specific diagnosis codes) plus at least two long-COVID-compatible diagnoses 28-
186 179 days after infection. These diagnoses were identified in prior work as post-acute associations
187 with COVID-19^{12,32} (Supplemental Table S3).

188 Some results are reported for pre-omicron and omicron eras. This applies only to
189 adolescents, as vaccines for younger children were not available substantially before the omicron
190 era. To maintain consistency across analyses, November 29, 2021, the first day a younger child
191 could have had a qualifying post-vaccine infection, was used as the dividing line between eras; at
192 that point omicron was circulating in the US, and became the dominant strain a few weeks later.
193 For each patient, the date of a SARS-CoV-2 infection following cohort entry, if one occurred,

194 was used to place their results in either of the two eras; if the patient never developed COVID-
195 19, the date of cohort entry was used.

196 *Exposure:* The primary exposure was receipt of at least one dose of SARS-CoV-2 vaccine.
197 Vaccine doses were ascertained using a vaccine code (CVX or RxNorm) designating an
198 administered or patient-reported dose, a procedure code indicating SARS-CoV-2 vaccination, or
199 a vaccine description containing the string “COVID” or “SARS”. Where available, data was
200 retrieved from state/regional vaccine information systems via hospital operational procedures.
201 Adequate vaccine data capture was defined as a site-reported vaccination rate at least 60% of the
202 CDC-estimated rate² for its coverage area, based on addresses of patients seen during the
203 pandemic. Where dose counts were used, all recorded doses within 14 days of a base dose were
204 considered a single dose.

205 *Demographic and clinical data.* Age, sex, and ethnicity were taken from EHRs. Comorbidity
206 data used the body system taxonomy of the Pediatric Medical Complexity Algorithm (PMCA)¹⁴.
207 Diagnoses received up to 3 years before cohort entry were considered. To classify patients as
208 complex-chronic, chronic, or no chronic condition, the “more conservative” version of the
209 algorithm was applied.

210 *Main analysis.* We matched vaccinated and unvaccinated patients on age group at cohort
211 entry (5-11, 12-17) and time period (six-month cohort entry period). We limited long COVID
212 observations to 12 months following cohort entry to account for waning of vaccine effectiveness
213 (VE) over time.

214 *Sensitivity analyses:* To evaluate potential impact of attrition due to matching, we
215 performed a sensitivity analysis using inverse probability of treatment weighting that
216 incorporated age group, time of cohort entry, sex, ethnicity, health system, number of baseline

217 visits to the health system, PMCA-defined body system(s) affected by chronic illness,
218 progressive disease, and malignancy. Further, we estimated VE after changing the window for
219 outcomes to 6 months and 18 months post cohort entry and restricting the vaccinated cohort to
220 those with at least 2 recorded doses.

221 *Cohort Comparison.* For unadjusted analyses, follow-up time was computed from cohort
222 entry until the end of observation. We calculated an incidence rate ratio (IRR) comparing
223 vaccinated to unvaccinated groups and derived 95% CIs using the estimation of Wald³³.
224 Corresponding VE was computed as $100 \times (1 - \text{IRR})$.

225 For adjusted analyses, we used conditional logistic regression to account for stratification.
226 Covariates included sex, ethnicity, health system, baseline utilization (0, 1-5, 6-10, 11-24, 25-49,
227 50-99, or 100+ encounters in the 3 years prior to cohort entry), the number of PMCA body
228 systems affected, and the presence of progressive or malignant condition. Since the prevalence of
229 long COVID was low, $\text{IRR} \approx \text{OR}$, so the corresponding VE was computed as $100 \times (1 - \text{OR})$.

230 *Mediation Analyses.* To understand the direct and indirect impact of vaccination on long
231 COVID, we conducted causal mediation analyses, where the treatment was pre-infection
232 vaccination, the mediator was SARS-CoV-2 infection, and the outcome was long COVID. We fit
233 two logistic regression models, the first of treatment on the mediator, and the second of treatment
234 and mediator on the outcome, adjusting for the same set of covariates. From these models, we
235 estimated the effect and CIs of vaccination on long COVID independent of infection, and of
236 vaccination on long COVID mediated by infection.

237 *Statistical Tools.* Data analysis was performed using R¹⁷ version 4.0.2. Exact matching
238 used the `matchIt` package³⁴ version 4.4.0, while IPTW were computed via `twang`³⁵ version

239 2.5. Conditional logistic regression used the `clogit()` algorithm implemented in the
240 `survival` package³⁶ version 3.5. Significant effects were identified based on a threshold of
241 $\alpha < 0.05$.

242 **Results**

243 *Study Cohort*

244 Immunization data from 17 health systems was sufficiently robust for inclusion. Cohort
245 formation is described in Figure 1: the 5–11-year-old group comprised 480,498 children, while
246 the 12-17 year-old group comprised 719,519 children/adolescents. Overall, 55% received at
247 least one SARS-CoV-2 vaccine, and 84% of vaccinated children received two or more doses.
248 Compared to unvaccinated children, vaccinated patients were older, had lower baseline
249 healthcare utilization, and fewer chronic conditions. Girls and children who identified as Asian
250 or Hispanic were more common in the vaccinated group, while those identifying as Black and
251 White were less common (Table 1). Descriptive statistics for the matched cohorts are provided in
252 Supplemental Table S1. Vaccinated patients had slightly fewer comorbidities and healthcare
253 utilization than unvaccinated patients. The prevalence of probable long COVID was 0.3% in the
254 cohort overall; for children with COVID-19 after cohort entry, prevalence of diagnosed long
255 COVID was 0.8%, and adding probable cases raised the prevalence of long COVID to 4.5%.

256 *Effect of Vaccination on long COVID in Children and Adolescents*

257 While the likelihood that a recorded vaccine is incorrectly attributed to a patient is very low, the
258 risk that dose count is incomplete in reported data is well-described³⁷, and discontinuation before
259 a second dose is uncommon. It is therefore more accurate in this study design to include patients
260 with evidence of vaccination, and, because any compensatory bias introduced thereby will tend
261 to reduce estimates, more responsible to report results that do not overestimate vaccine

262 effectiveness. We analyzed all children with evidence of vaccination prior to SARS-CoV-2
263 infection. Results were very similar across approaches: VE was 35% (95% CI 24– 45%) for the
264 combined age groups (Table 2), with greater effect in adolescents than younger children. For
265 children known to be completely vaccinated (*i.e.* 2+ doses) prior to SARS-CoV-2 infection, VE
266 was 35% (95% CI 35– 53%) against probable long COVID within 12 months (Figure 2), with
267 consistent findings within age strata, supporting the validity of our approach. For comparison,
268 VE estimates against SARS-CoV-2 infection are shown in Supplemental Figure S1. We
269 observed decreased likelihood of long COVID among boys and children with non-Hispanic
270 Black or Asian ethnicity (Supplementary Table S2). The presence of chronic conditions had
271 minimal effect, though likelihood of long COVID rose with increasing baseline utilization.
272 The protective effect of vaccination appeared to wane over time. We observed higher VE
273 against long COVID within 6 months of vaccination than 12 months, while extending the
274 observation period to 18 months revealed a further diminution (Figure 3). Protection was also
275 seen in children who started vaccination after recuperating from COVID-19 (Supplemental
276 Figure S2).

277 One-to-one matching resulted in loss of 27% of unvaccinated and 64% of vaccinated patients due
278 to the high overall vaccination rate. To assess the effect of this on our VE estimates, we used
279 IPTW to adjust for multiple potential confounders without decreasing cohort size. Once again, a
280 protective effect was seen, though with a smaller magnitude of 24% (95% CI 20 – 28%) for
281 vaccination on long COVID up to a year later (Supplemental Figure S3).

282 To assess where in the path to long COVID the vaccine might have impact, we performed
283 mediation analysis, estimating effect of vaccine on long COVID via change in COVID-19 risk
284 (indirect effect) separately from other effects on long COVID (direct effect). For 5–11-year-

285 olds, who became vaccine eligible just before the omicron variant became prevalent, the long
286 COVID-associated OR for indirect effect on probable long COVID was 0.67 (95% CI 0.64 –
287 0.70), while for direct effect the OR was 1.34 (95% CI 1.13 – 1.59). For adolescents, results
288 were similar: in the pre-omicron era the indirect effect OR was 0.46 (95% CI 0.45 – 0.48) and
289 direct effect OR was 1.32 (95% CI 1.12 – 1.55); in the omicron era, the analogous ORs were
290 0.45 (95% CI 0.41 – 0.49) and 0.99 (95% CI 0.73 – 1.34). These results suggest that throughout
291 the period of pediatric use, the effectiveness of vaccine against long COVID is closely tied to its
292 effectiveness against the antecedent COVID-19 episode.

293 **Discussion**

294 To our knowledge, this national-scale study, with a diverse cohort of over 1 million children, is
295 the first to estimate the VE against long COVID in children. Our findings suggest that SARS-
296 CoV-2 vaccine is associated with reduced risk of Long COVID in children and adolescents. The
297 protective effect was greater among adolescents than younger children, reflecting activity against
298 delta and omicron strains, while use for younger children is limited to the omicron era. Since
299 diagnostic codes for long COVID (*e.g.* ICD-10-CM U09.9) are rare in children, we have
300 examined both specific diagnosis as an outcome, and a broader definition based on the repeated
301 presence from 1-6 months after infection of symptoms that occur more frequently following
302 COVID-19 than in uninfected children^{12,32}. The effect of vaccine is similar for both outcomes
303 and is also seen in children vaccinated after an initial episode of COVID-19, suggesting that
304 vaccination confers some benefit against future late effects. Mediation analysis suggests that the
305 protective effect of vaccination may be primarily via reduction in the occurrence or severity of
306 infection.

307 Our finding of a protective effect against long COVID in children are consistent with those
308 observed in adults, while the VE estimates in our study are lower than studies assessing the
309 short-term effect of vaccines in the one week to one month after vaccination ²⁹. Other reasons are
310 varied definitions of long COVID between these studies, and different methodological
311 approaches. Our observed higher VE for adolescents is similar to studies examining acute
312 infection ³⁸. Further analyses are required to explore whether other factors contribute to this
313 difference, such as long COVID symptoms being more frequently reported or documented in
314 adolescents.

315 Waning effects of vaccine against long COVID are to be expected ³⁹, similar to studies against
316 acute infection ^{40 41 42}. The reasons include reduced neutralization efficiency against newer
317 strains and waning of pre-existing antibodies over time ⁴³. It is also possible that long COVID
318 starting several months after acute infection, or delayed diagnosis or recognition of long COVID,
319 may contribute to this phenomenon. Further, waning effect may reflect the impact of successive
320 infections rather than late-onset long COVID. This is difficult to assess analytically, given fewer
321 COVID-19 episodes are being documented in the EHR during the omicron era. Evaluations of
322 VE over time are needed to address whether these waning effects can be overcome through
323 booster or annual vaccine doses.

324 VE studies using EHR data rely on accurate capture of clinical and vaccine data, with adjustment
325 for important confounders to minimize potential bias ^{44 45}. Our focus on data quality, including
326 comparison to the CDC's county-level vaccination data, reduced our cohort size but yielded
327 more reliable vaccination data. Our assessment of VE against acute SARS-CoV-2 was similar to
328 VE estimates from other pediatric studies, further validating our findings and approach. Finally,

329 we performed matching on age and time period to limit secular effects and conducted sensitivity
330 analyses including inverse probability of treatment weighting, with similar findings.

331 Nonetheless, several challenges exist with the identification of long COVID in children using
332 EHR data, which may confound assessment of our outcome. There has been low uptake of the
333 long COVID (ICD10-CM U09.9) diagnosis code in pediatrics; it is more often seen in older
334 children and associated with respiratory, cardiovascular, or fatigue subtypes of long COVID³².
335 For this reason, we supplemented our outcome definition with a symptom-based computable
336 phenotype definition of long COVID we have developed, which includes features related to long
337 COVID based on statistical association and chart review validation^{12,32}. However, long COVID
338 presentations are heterogeneous, and symptoms and conditions may overlap with other childhood
339 illnesses, with the potential for misclassification of long COVID in our study. These limitations
340 on classification accuracy are expected to affect both vaccinated and unvaccinated cohorts,
341 similarly, so would not confound the comparison of the two.

342 There are other limitations that warrant discussion. First, our study relies on secondary use of
343 EHR data, and is subject to bias due to differential access to and utilization of healthcare during
344 the pandemic, as well as clinical practice variation across sites. We required both pre- and post-
345 vaccine visits to establish a baseline of utilization, which may create bias toward sicker patients,
346 but importantly we did not observe major imbalances in utilization rates between cohorts. Next,
347 testing practices changed over time, with an increased reliance on home antigen testing in later
348 phases of the pandemic, potentially leading to misclassification of symptom based long COVID.
349 In addition, a large proportion of patients in our data with a long COVID diagnosis code do not
350 have documentation in the EHR of the antecedent COVID-19 episode, which prevented use of
351 severity as an adjustment to vaccine effect.

352 Conclusion

353 Our results provide substantial evidence in a large and diverse cohort of children receiving health
354 care for protective effect in children 5 years and older. This study adds to the growing body of
355 knowledge about mitigating effect of vaccines on COVID-19, while demonstrating the need for
356 further research utilizing a range of designs to examine the protective effect of these vaccines
357 against subsequent strains and to help guide vaccine policy.

358 Acknowledgments

359
360 We are grateful to the health systems, clinicians, and patients at member sites without
361 whose trust research of this type would not be possible. We are also grateful to clinical data
362 teams at each RECOVER site involved in data extraction and integration, as well as colleagues at
363 the RECOVER Coordinating Center, particularly Susan Hague, for maintaining the RECOVER
364 data infrastructure. Additionally, we would like to thank the National Community Engagement
365 Group (NCEG), all patient, caregiver and community Representatives, and all the participants
366 enrolled in the RECOVER Initiative
367

368 References

- 369 1. Johns Hopkins University. COVID-19 dashboard by the Center for Systems Science and
370 Engineering (CSSE) at Johns Hopkins University (JHU). Accessed March 04, 2023.
371 <https://coronavirus.jhu.edu/map.html>
- 372 2. Centers for Disease Control and Prevention (CDC). CDC COVID Data Tracker.
373 Accessed March 04, 2023. <https://covid.cdc.gov/covid-data-tracker/#demographics>
- 374 3. Forrest CB, Burrows EK, Mejias A, et al. Severity of Acute COVID-19 in Children <18
375 Years Old March 2020 to December 2021. *Pediatrics*. Apr 1 2022;149(4)doi:10.1542/peds.2021-
376 055765
- 377 4. Pinto Pereira SM, Nugawela MD, Rojas NK, et al. Post-COVID-19 condition at 6 months
378 and COVID-19 vaccination in non-hospitalised children and young people. *Arch Dis Child*. Apr
379 2023;108(4):289-295. doi:10.1136/archdischild-2022-324656
- 380 5. Trapani G, Verlatto G, Bertino E, et al. Long COVID-19 in children: an Italian cohort
381 study. *Ital J Pediatr*. Jun 3 2022;48(1):83. doi:10.1186/s13052-022-01282-x
- 382 6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,
383 mechanisms and recommendations. *Nat Rev Microbiol*. Mar 2023;21(3):133-146.
384 doi:10.1038/s41579-022-00846-2
- 385 7. Kuczborska K, Buda P, Ksiazek J. Long-COVID in immunocompromised children. *Eur J*
386 *Pediatr*. Sep 2022;181(9):3501-3509. doi:10.1007/s00431-022-04561-1
- 387 8. Pierce CA, Herold KC, Herold BC, et al. COVID-19 and children. *Science*. Sep 9
388 2022;377(6611):1144-1149. doi:10.1126/science.ade1675
- 389 9. Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem
390 inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19:

- 391 optimizing definition and management. *Pediatr Res*. May 2023;93(6):1499-1508.
392 doi:10.1038/s41390-022-02263-w
- 393 10. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19
394 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health*. Jun
395 2021;5(6):e22-e23. doi:10.1016/S2352-4642(21)00124-3
- 396 11. Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild
397 SARS-CoV-2 infection: nationwide cohort study. *BMJ*. Jan 11 2023;380:e072529.
398 doi:10.1136/bmj-2022-072529
- 399 12. Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of
400 SARS-CoV-2 Infection in Children and Adolescents. *JAMA Pediatr*. Aug 22
401 2022;doi:10.1001/jamapediatrics.2022.2800
- 402 13. Adler L, Israel M, Yehoshua I, et al. Long COVID symptoms in Israeli children with and
403 without a history of SARS-CoV-2 infection: a cross-sectional study. *BMJ Open*. Feb 21
404 2023;13(2):e064155. doi:10.1136/bmjopen-2022-064155
- 405 14. Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 Conditions Among Children
406 90 Days After SARS-CoV-2 Infection. *JAMA Netw Open*. Jul 1 2022;5(7):e2223253.
407 doi:10.1001/jamanetworkopen.2022.23253
- 408 15. Katika A, Zoulias E, Koufi V, Malamateniou F. Mining Greek Tweets on Long COVID
409 Using Sentiment Analysis and Topic Modeling. *Stud Health Technol Inform*. Jun 29
410 2023;305:545-548. doi:10.3233/SHTI230554
- 411 16. Kasi SG, Dhir SK, Shah A, et al. Coronavirus Disease 2019 (COVID-19) Vaccination for
412 Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on
413 Vaccination and Immunization Practices. *Indian Pediatr*. Jan 15 2022;59(1):51-57.
414 doi:10.1007/s13312-022-2421-9
- 415 17. Barie PS, Brindle ME, Khadaroo RG, Klassen TL, Huston JM. Omicron, Long-COVID,
416 and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the
417 Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery
418 Strategic Clinical Network, Alberta Health Services. *Surg Infect (Larchmt)*. Feb 2023;24(1):6-
419 18. doi:10.1089/sur.2022.274
- 420 18. Paul S, Mishra CM. Do we need to vaccinate every child against COVID-19: What
421 evidence suggests-A systematic review of opinions. *Front Public Health*. 2022;10:1002992.
422 doi:10.3389/fpubh.2022.1002992
- 423 19. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
424 CoV-2 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 425 20. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2
426 Vaccine at Completion of Blinded Phase. *N Engl J Med*. Nov 4 2021;385(19):1774-1785.
427 doi:10.1056/NEJMoa2113017
- 428 21. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2
429 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med*. Nov 4 2021;385(19):1761-1773.
430 doi:10.1056/NEJMoa2110345
- 431 22. Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2,
432 and vaccine effectiveness associated with the Delta variant. *Science*. Dec 17
433 2021;374(6574):eab19551. doi:10.1126/science.ab19551
- 434 23. Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2
435 Vaccines against Omicron Variant in South Africa. *N Engl J Med*. Jun 9 2022;386(23):2243-
436 2245. doi:10.1056/NEJMc2202061

- 437 24. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
438 CoV-2 Omicron and Delta variants. *Nat Med.* May 2022;28(5):1063-1071. doi:10.1038/s41591-
439 022-01753-y
- 440 25. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat*
441 *Med.* Jul 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0
- 442 26. Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination
443 in an EHR-based cohort study from the RECOVER program. *Nat Commun.* May 22
444 2023;14(1):2914. doi:10.1038/s41467-023-38388-7
- 445 27. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2
446 infection: A retrospective cohort study of 10,024 breakthrough infections. *Brain Behav Immun.*
447 Jul 2022;103:154-162. doi:10.1016/j.bbi.2022.04.013
- 448 28. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms
449 after covid-19 vaccination: community based cohort study. *BMJ.* May 18 2022;377:e069676.
450 doi:10.1136/bmj-2021-069676
- 451 29. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk
452 of developing long-COVID and on existing long-COVID symptoms: A systematic review.
453 *EClinicalMedicine.* Nov 2022;53:101624. doi:10.1016/j.eclinm.2022.101624
- 454 30. Arjun MC, Singh AK, Pal D, et al. Characteristics and predictors of Long COVID among
455 diagnosed cases of COVID-19. *PLoS One.* 2022;17(12):e0278825.
456 doi:10.1371/journal.pone.0278825
- 457 31. Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-
458 acute sequelae of COVID-19 (PASC): A prospective cohort study. *Vaccine.* Jul 30
459 2022;40(32):4424-4431. doi:10.1016/j.vaccine.2022.05.090
- 460 32. Lorman V, Rao S, Jhaveri R, et al. Understanding pediatric long COVID using a tree-
461 based scan statistic approach: an EHR-based cohort study from the RECOVER Program. *JAMIA*
462 *Open.* Apr 2023;6(1):ooad016. doi:10.1093/jamiaopen/ooad016
- 463 33. Sahai H, Khurshid A. *Statistics in epidemiology : methods, techniques, and applications.*
464 CRC Press; 1996:321 p.
- 465 34. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric
466 Causal Inference. *Journal of Statistical Software.* 06/14 2011;42(8):1 - 28.
467 doi:10.18637/jss.v042.i08
- 468 35. Ridgeway GM, D. F.; Morral, A. R.; Cefalu, M.; Burgette, L. F.; Pane, J. D.; Griffin, B.
469 A. *Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the R TWANG*
470 *Package.* 2022.
- 471 36. Therneau TM. A Package for Survival Analysis in R. Accessed 2023-08-07, 2023.
- 472 37. Centers for Disease Control and Prevention Data (CDC). Definitions for COVID-19
473 Vaccinations in the United States. Accessed August 25, 2022.
474 [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/reporting-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/reporting-vaccinations.html#anchor_1649867074684)
475 [vaccinations.html#anchor_1649867074684](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/reporting-vaccinations.html#anchor_1649867074684)
- 476 38. Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer
477 BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11
478 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
479 *MMWR Morb Mortal Wkly Rep.* Mar 18 2022;71(11):422-428. doi:10.15585/mmwr.mm7111e1
- 480 39. Yewdell JW. Individuals cannot rely on COVID-19 herd immunity: Durable immunity to
481 viral disease is limited to viruses with obligate viremic spread. *PLoS Pathog.* Apr
482 2021;17(4):e1009509. doi:10.1371/journal.ppat.1009509

- 483 40. Klein NP, Demarco M, Fleming-Dutra KE, et al. Effectiveness of BNT162b2 COVID-19
484 Vaccination in Children and Adolescents. *Pediatrics*. May 1 2023;151(5)doi:10.1542/peds.2022-
485 060894
- 486 41. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron
487 Variant in Children and Adolescents. *N Engl J Med*. May 19 2022;386(20):1899-1909.
488 doi:10.1056/NEJMoa2202826
- 489 42. Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2
490 Vaccine against Omicron in Children 5 to 11 Years of Age. *N Engl J Med*. Aug 11
491 2022;387(6):525-532. doi:10.1056/NEJMoa2203209
- 492 43. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2
493 breakthrough infections in vaccinated individuals: measurement, causes and impact. *Nat Rev*
494 *Immunol*. Jan 2022;22(1):57-65. doi:10.1038/s41577-021-00662-4
- 495 44. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative
496 Study Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol*. Sep 1
497 2016;184(5):345-53. doi:10.1093/aje/kww064
- 498 45. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for
499 causality: lessons from vaccine effectiveness and impact studies. *Int J Epidemiol*. Dec 1
500 2016;45(6):2060-2074. doi:10.1093/ije/dyw124
- 501 46. RECOVER: Researching COVID to Enhance Recovery. (n.d.). RECOVER: Researching
502 COVID to Enhance Recovery. <https://recovercovid.org/>

503

504 **Table 1. Cohort Description for Full Cohort**

	Vaccinated (N = 692912)	Unvaccinated (N = 345024)	Overall (N = 1037936)
Race/Ethnicity			
Asian	45267 (6.5%)	8380 (2.4%)	53647 (5.2%)
Black/AA (non-Hispanic)	84642 (12.2%)	63183 (18.3%)	147825 (14.2%)
Hispanic	168102 (24.3%)	70976 (20.6%)	239078 (23.0%)
Multiple/Other/ Missing/Unknown	91494 (13.2%)	36674 (10.6%)	128168 (12.3%)
White (non-Hispanic)	303407 (43.8%)	165811 (48.1%)	469218 (45.2%)
Age (yr) at Entry^a			
Mean (SD)	12.4 (3.58)	11.1 (3.66)	11.9 (3.65)
Median [Min, Max]	12.8 [5.02, 18.0]	11.0 [5.01, 18.0]	12.2 [5.01, 18.0]
Age Group at Entry^a			
5-11 years	279279 (40.3%)	201019 (58.3%)	480298 (46.3%)
12-17 years	413633 (59.7%)	144005 (41.7%)	557638 (53.7%)
Sex			
Female/Missing	353971 (51.1%)	168787 (48.9%)	522758 (50.4%)
Male	338941 (48.9%)	176237 (51.1%)	515178 (49.6%)

	Vaccinated (N = 692912)	Unvaccinated (N = 345024)	Overall (N = 1037936)
Time Period of Entry^a			
Dec 2020 – May 2021	197799 (28.5%)	38763 (11.2%)	236562 (22.8%)
Jun – Nov 2021	319605 (46.1%)	65391 (19.0%)	384996 (37.1%)
Dec 2021 – May 2022	157720 (22.8%)	135878 (39.4%)	293598 (28.3%)
Jun – Nov 2022	17788 (2.6%)	104992 (30.4%)	122780 (11.8%)
In-Person Visits in Baseline Period			
00 visits ^b	44741 (6.5%)	12236 (3.5%)	56977 (5.5%)
01 to 05 visits	261683 (37.8%)	122599 (35.5%)	384282 (37.0%)
06 to 10 visits	168774 (24.4%)	90751 (26.3%)	259525 (25.0%)
11 to 24 visits	149470 (21.6%)	83087 (24.1%)	232557 (22.4%)
≥25 visits	68244 (9.9%)	36351 (10.5%)	104595 (10.1%)
Chronic Disease Category^c			
Non-complex Chronic	63877 (9.2%)	33448 (9.7%)	97325 (9.4%)
Complex Chronic	20983 (3.0%)	12903 (3.7%)	33886 (3.3%)
None	608052 (87.8%)	298673 (86.6%)	906725 (87.4%)
Progressive Condition^c			
No	654097 (94.4%)	321720 (93.2%)	975817 (94.0%)
Yes	38815 (5.6%)	23304 (6.8%)	62119 (6.0%)
Malignancy^c			
No	687759 (99.3%)	341609 (99.0%)	1029368 (99.2%)
Yes	5153 (0.7%)	3415 (1.0%)	8568 (0.8%)
Institution			
A	23144 (3.3%)	14769 (4.3%)	37913 (3.7%)
B	65697 (9.5%)	29160 (8.5%)	94857 (9.1%)
C	142143 (20.5%)	43523 (12.6%)	185666 (17.9%)
D	65036 (9.4%)	46009 (13.3%)	111045 (10.7%)
E	15003 (2.2%)	3495 (1.0%)	18498 (1.8%)
F	109402 (15.8%)	55253 (16.0%)	164655 (15.9%)
G	17214 (2.5%)	2057 (0.6%)	19271 (1.9%)
H	335 (0.0%)	1696 (0.5%)	2031 (0.2%)
I	47910 (6.9%)	33443 (9.7%)	81353 (7.8%)
J	26925 (3.9%)	12387 (3.6%)	39312 (3.8%)
K	45811 (6.6%)	17818 (5.2%)	63629 (6.1%)
L	39651 (5.7%)	42678 (12.4%)	82329 (7.9%)
M	14732 (2.1%)	11696 (3.4%)	26428 (2.5%)
N	2416 (0.3%)	1371 (0.4%)	3787 (0.4%)
O	13352 (1.9%)	6928 (2.0%)	20280 (2.0%)

	Vaccinated (N = 692912)	Unvaccinated (N = 345024)	Overall (N = 1037936)
P	23249 (3.4%)	7076 (2.1%)	30325 (2.9%)
Q	14418 (2.1%)	8021 (2.3%)	22439 (2.2%)
R	26474 (3.8%)	7644 (2.2%)	34118 (3.3%)

505 ^a Vaccination date or visit date if unvaccinated

506 ^b Patients with baseline eligibility data based on administrative (*e.g.* telephone) visits

507 ^c Based on PMCA

508

509 **Table 2. SARS-CoV-2 Vaccine Effectiveness Against Long COVID**

510

	N ^a	Vaccine Effectiveness (%), 95% CI	
		Unadjusted	Adjusted^b
Symptom-based or Diagnosed long COVID			
Child (5-11 y), omicron	753	19.7 (7.1 – 30.6)	23.8 (4.9 – 39.0)
Adolescent (12-17 y), all patients	961	28.7 (18.8 – 37.4)	50.3 (36.6 – 61.0)
Adolescent (12-17 y), pre-omicron	726		35.3 (4.8 – 56.0)
Adolescent (12-17y), omicron			58.7 (39.1 – 72.0)
All ages (5-17 y)	1,669	25.3 (17.6 – 32.2)	35.4 (24.5 – 44.5)
Diagnosed long COVID only			
Child (5-11 y)	82	16 (-32.7 – 46.9)	48.2 (-.21 – 77.8)
Adolescent (12-17 y)	194	41.7 (21.4 – 57.0)	56.1 (25.8 – 74.0)
All ages (5-17 y)	270	35.6 (17.4 – 50.0)	41.7 (15.0 – 60.0)

511 ^a Cases of long COVID. Note that values for 5-11 and 12-17 year age strata do not sum to the value for
512 5-17 as each stratum is drawn from sites with usable vaccine data for all ages in that stratum.

513 ^b Adjusted for sex, ethnicity, health system, baseline utilization in the 3 years prior to cohort entry, the
514 number of body systems affected in the same interval, and the presence of a condition defined in the
515 PMCA as either progressive or malignant

516

517

518

519

520

521

522 **Figure 1: Study Sample Selection.** Steps in the construction of the overall study sample are
523 shown, including demographic and vaccine-related eligibility criteria. At each step, the number
524 of children satisfying all criteria to that point is shown, as is the percentage of children in the
525 previous step who were retained. ^a Vaccination rates $\geq 70\%$ of CDC regional estimate

526 **Figure 2. Vaccine effectiveness estimates for children receiving at least 2 doses of mRNA**
527 **vaccine in their primary series.** Analyses were otherwise structured identically to the main
528 analysis.

529 **Figure 3. Durability of vaccine effectiveness of SARS-CoV-2 vaccine against long COVID.**
530 Results are shown for PASC occurring within 6, 12, or 18 months of vaccination.





